SCHEMBL7287487

SCHEMBL7287487

NC(=O)c1ccccc1NC(=O)c1cccnc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 2/20 0.76
HDAC3 O15379 2/20 0.69
HDAC1 Q13547 2/20 0.69
HDAC2 Q92769 2/20 0.69
TP53 P04637 1/20 0.64
HTT P42858 2/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
ALDH1A1 P00352 1/20 0.62
ALOX15 P16050 1/20 0.62
MAPT P10636 1/20 0.60
PDCD1 Q15116 1/20 0.58
CD274 Q9NZQ7 1/20 0.58
RXFP1 Q9HBX9 1/20 0.57
LMNA P02545 1/20 0.56
HIF1A Q16665 1/20 0.56
F7 P08709 1/20 0.56
F3 P13726 1/20 0.56
SARM1 Q6SZW1 1/20 0.56
SIRT6 Q8N6T7 1/20 0.56
SIRT1 Q96EB6 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8819152 0.87 KDM4D (0.68) SIRT2HDAC3HDAC1HDAC2TP53
SCHEMBL15966615 0.85 TP53 (0.68) SIRT2HDAC3HDAC1HDAC2TP53
SCHEMBL31087254 0.85 TP53 (0.68) SIRT2HDAC3HDAC1HDAC2TP53
SCHEMBL2154765 0.84 PDCD1 (0.60) SIRT2HDAC3HDAC1HDAC2TP53
SCHEMBL22983344 0.83 TP53 (0.77) HDAC3HDAC1HDAC2TP53HTT
SCHEMBL786246 0.82 PDCD1 (0.81) SIRT2HDAC3HDAC1HDAC2TP53
SCHEMBL7290635 0.82 HDAC1 (0.60) SIRT2HDAC3HDAC1HDAC2L3MBTL1
SCHEMBL18086514 0.82 HDAC1 (1.00) HDAC3HDAC1HDAC2HTTL3MBTL1
SCHEMBL571346 0.81 SIRT2 (0.60) SIRT2HDAC3HDAC1HDAC2HTT
SCHEMBL1520536 0.80 HDAC1 (0.70) HDAC3HDAC1HDAC2TP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020025968-A1 Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives OSI PHARMACEUTICALS, INC. 2002-02-28 US disclosed
EP-0579496-B1 4-Aminoquinazoline derivatives, and their use as medicine ONO PHARMACEUTICAL CO (JP) 2001-11-14 EP disclosed
US-5439895-A Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate ONO PHARMACEUTICAL CO., LTD. (JP) 1995-08-08 US disclosed
US-5436233-A Nervous system disorders ONO PHARMACEUTICAL CO., LTD. (JP) 1995-07-25 US disclosed
EP-0579496-A1 4-Aminoquinazoline derivatives, and their use as medicine ONO PHARMACEUTICAL CO., LTD. (JP) 1994-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020025968-A1 Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives VHL, MCL1, NFATC1 SIRT2 3193/4885HDAC3 1848/4885HDAC1 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.